revealed dr Muhammad Awad Taj El-Din, Advisor to the President for Health and Prevention Affairs, in an exclusive statement to “The Seventh Day”, that Respiratory syncytial virus It is a virus within a group of respiratory viruses that have existed for a long time, and it is a very large group of about 20 to 30 species.
And he continued: that when the child complains, the symptoms are a high fever, chest wheezing, coughing, inflammation and pain in the throat, and when presented to the doctor, the patient is diagnosed as suffering from a respiratory virus because all viruses give symptoms similar to influenza, even the Corona virus currently causes flu-like symptoms, But these days, the presence of Corona and other viruses made people interested in the respiratory syncytial virus, but it is an old and widespread virus and not an epidemic. We treat this type of virus easily, just like the flu, so there is no need for concern, and it does not cause serious complications.
On the other hand, Pfizer had announced that its experimental vaccine for the respiratory syncytial virus (RSV) It was shown to be effective in preventing severe infections in infants after being given in a late-stage study to expectant mothers in the second trimester of pregnancy, according to the Pfizer website and the Archyde.com website..
Pfizer’s shot, if approved, could be the first maternal vaccine available to reduce disease burden in young infants, and the company plans to submit it for approval by the end of 2022..
“Vaccinating mothers benefits from being able to protect an infant from day one, which is important because these infants peak in hospital admissions for respiratory syncytial virus,” said Kenna Swanson, vice president of viral vaccines at Pfizer. RSV He is about one to two months old.
Two companies are competing, PfizerPfizer and GlaxoSmithKline GSK To develop a vaccine against respiratory syncytial virus RSVA leading cause of pneumonia in young children and the elderly, the vaccine should generate billions of dollars in sales upon approval.
Estimated data, The respiratory syncytial virus RSVIt leads to 58,000 children under the age of five being admitted to US hospitals each year.
The Pfizer vaccine showed 81.8% efficacy in preventing a severe form of lower respiratory disease in infants in the first 90 days. Signs of severe illness in the study included extremely low oxygen levels, being put on a ventilator, being in an intensive care unit, or losing Awareness due to respiratory syncytial virus.
According to Archyde.com, the unmet endpoint was reducing disease in infants that required care by a health care provider, explaining that respiratory syncytial virus infection is increasing among young children in the United States, and there are currently no vaccines against the virus. syncytial respiratory RSV In August, Pfizer said its respiratory syncytial virus (RSV) vaccine RSV It was effective among older adults in a late-stage study.
While she said Glaxo said GSK In October, the vaccine was 82.6% effective in a late-stage study involving older adults.
Pfizer Inc. President Angela Lukin said at a conference in October that potential approval of Pfizer’s vaccine for pregnant women as well as adults would make it “the only company with an indication for both the mother and the elderly.”“.
According to the US Centers for Disease Control and Prevention website” CDC”is a respiratory syncytial virus RSV is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover within a week or two, but RSV can be serious, especially in infants and the elderly, as it is the most common cause of bronchiolitis (inflammation of the small airways in lung) and pneumonia (infection of the lungs) in children under 1 year of age in the United States.